Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Actinogen Medical Ltd

ACW.AX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: BUY

Last Close

$0.03

▼ -2.33%

Market Cap $114.34M · Vol 5.31M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$114.34M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

37.50

Momentum

Beta

1.11

vs Market

52W High

$0.05

39.00% below

52W Low

$0.02

38.26% above

Volume

5.31M

Avg 5.00M

P/B

5.39

Price-to-book

ROE

N/A

Return on equity

Free Float

77.98%

Public shares

Shariah Compliance8 STANDARDS

✗ Actinogen Medical Ltd (ACW.AX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ACW.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.70%

-25.00%

+2.44%

-2.33%

YTD

-31.15%

+23.53%

+177.81%

-69.42%

Financials & Valuation

TTM · Annual

Total Revenue	$345.85K
Net Income	$-10,641,286.00
Revenue Growth (YoY)	-39.45%
Gross Margin	100.00%
Operating Margin	-5,524.32%
Net Profit Margin	-3,076.84%
ROE	N/A
ROA · ROIC	-56.92% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	206.64
P/B	5.39
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	3.87B

Technical Indicators

50-Day SMA	$0.04
200-Day SMA	$0.03
RSI (14)	37.50
Beta	1.11
52-Week High	$0.05
52-Week Low	$0.02

Volume Today	5.31M
Avg Daily Volume (30D)	5.00M
Relative Volume	1.06x
Volatility (10D)	87.71
Volatility (30D)	81.76
Free Float	77.98%

Analyst Consensus

BUY

Current Price $0.03

Mean Target $0.05

52W Low$0.02 52W High$0.05

Current

Target

$0.02 $0.05

Current Analyst target

+75.57% upside potential · 0 analysts

Identifiers

ExchangeASX

FIGIBBG001SRC0W8

ISINAU000000ACW3

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateMar 1, 2027

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.98% ARGX.BR argenx SE +0.35% ARGX argenx SE -0.55% GMAB.CO Genmab A/S +3.27% GMAB Genmab A/S +1.01%

Company Profile

Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism is to control elevated levels of cortisol (stress hormone) in the brain through the inhibition of the cortisol synthesis enzyme, 11B-HSD1, without affecting production of cortisol by the adrenal glands, which is essential for the body’s normal functioning. Xanamem is a once-a-day pill designed to deliver high levels of cortisol control in key areas of the brain related to Alzheimer’s and other diseases such as the hippocampus and frontal cortex.